García Castillo Elena, Alonso Pérez Tamara, Ancochea Julio, Pastor Sanz Maria Teresa, Almagro Pere, Martínez-Camblor Pablo, Miravitlles Marc, Rodríguez-Carballeira Mónica, Navarro Annie, Lamprecht Bernd, Ramírez-García Luna Ana S, Kaiser Bernhard, Alfageme Inmaculada, Casanova Ciro, Esteban Cristóbal, Soler-Cataluña Juan J, de-Torres Juan P, Celli Bartolomé R, Marín Jose M, Ter Riet Gerben, Sobradillo Patricia, Lange Peter, Garcia-Aymerich Judith, Anto Josep M, Turner Alice M, Han MeiLan K, Langhammer Arnulf, Vikjord Sigrid Anna Aalberg, Sternberg Alice, Leivseth Linda, Bakke Per, Johannessen Ane, Oga Toru, Cosío Borja G, Echazarreta Andrés, Roche Nicolás, Burgel Pierre-Régis, Sin Don D, Puhan Milo A, López-Campos Jose Luis, Carrasco Laura, Soriano Joan B
Pneumology Dept, Hospital Universitario de la Princesa, Instituto de Investigación Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Madrid, Spain.
These authors contributed equally.
ERJ Open Res. 2020 Nov 2;6(4). doi: 10.1183/23120541.00253-2020. eCollection 2020 Oct.
In 2019, The Global Initiative for Chronic Obstructive Lung Disease (GOLD) modified the grading system for patients with COPD, creating 16 subgroups (1A-4D). As part of the COPD Cohorts Collaborative International Assessment (3CIA) initiative, we aim to compare the mortality prediction of the 2015 and 2019 COPD GOLD staging systems. We studied 17 139 COPD patients from the 3CIA study, selecting those with complete data. Patients were classified by the 2015 and 2019 GOLD ABCD systems, and we compared the predictive ability for 5-year mortality of both classifications. In total, 17 139 patients with COPD were enrolled in 22 cohorts from 11 countries between 2003 and 2017; 8823 of them had complete data and were analysed. Mean±sd age was 63.9±9.8 years and 62.9% were male. GOLD 2019 classified the patients in milder degrees of COPD. For both classifications, group D had higher mortality. 5-year mortality did not differ between groups B and C in GOLD 2015; in GOLD 2019, mortality was greater for group B than C. Patients classified as group A and B had better sensitivity and positive predictive value with the GOLD 2019 classification than GOLD 2015. GOLD 2015 had better sensitivity for group C and D than GOLD 2019. The area under the curve values for 5-year mortality were only 0.67 (95% CI 0.66-0.68) for GOLD 2015 and 0.65 (95% CI 0.63-0.66) for GOLD 2019. The new GOLD 2019 classification does not predict mortality better than the previous GOLD 2015 system.
2019年,慢性阻塞性肺疾病全球倡议组织(GOLD)修改了慢性阻塞性肺疾病患者的分级系统,创建了16个亚组(1A - 4D)。作为慢性阻塞性肺疾病队列协作国际评估(3CIA)倡议的一部分,我们旨在比较2015年和2019年慢性阻塞性肺疾病GOLD分期系统对死亡率的预测情况。我们研究了来自3CIA研究的17139例慢性阻塞性肺疾病患者,选取了那些数据完整的患者。患者按照2015年和2019年GOLD ABCD系统进行分类,我们比较了两种分类方法对5年死亡率的预测能力。2003年至2017年间,共有17139例慢性阻塞性肺疾病患者纳入了来自11个国家的22个队列研究;其中8823例患者数据完整并进行了分析。平均年龄±标准差为63.9±9.8岁,男性占62.9%。GOLD 2019将患者分类为病情较轻的慢性阻塞性肺疾病。对于两种分类,D组的死亡率都更高。在GOLD 2015中,B组和C组的5年死亡率没有差异;在GOLD 2019中,B组的死亡率高于C组。与GOLD 2015相比,GOLD 2019分类中A组和B组患者具有更好的敏感性和阳性预测值。GOLD 2015对C组和D组的敏感性优于GOLD 2019。2015年GOLD系统5年死亡率的曲线下面积值仅为0.67(95%可信区间0.66 - 0.68),2019年GOLD系统为0.65(95%可信区间0.63 - 0.66)。新的GOLD 2019分类在预测死亡率方面并不比之前的GOLD 2015系统更好。